**Name of Journal:** *World Journal of Clinical Cases*

**Manuscript NO:** 82107

**Manuscript Type:** MINIREVIEWS

**Application of laparoscopic surgery in gallbladder carcinoma**

Wu X *et al*. Laparoscopic surgery in GC

Xin Wu, Bing-Lu Li, Chao-Ji Zheng

**Xin Wu, Bing-Lu Li, Chao-Ji Zheng,** Department of General Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100730, China

**Author contributions:** All authors helped to perform the research; Wu X performed manuscript writing and data analysis; Li BL contributed to manuscript conception and design; Zheng CJ contributed to manuscript conception, design, and writing.

**Supported by** Chinese Academy of Medical Sciences Innovation Fund for Medical Sciences, No. 2022-I2M-C&T-A-004; and National High Level Hospital Clinical Research Funding, No. 2022-PUMCH-B-005.

**Corresponding author: Bing-Lu Li, MD, Professor,** Department of General Surgery, Peking Union Medical College Hospital, No. 1 Shuaifuyuan, Dongcheng District, Beijing 100730, China. pumchlibinglu@163.com

**Received:** December 10, 2022

**Revised:** March 4, 2023

**Accepted:** April 19, 2023

**Published online:**

**Abstract**

Gallbladder carcinoma (GC) is a rare type of cancer of the digestive system, with an incidence that varies by region. Surgery plays a primary role in the comprehensive treatment of GC and is the only known cure. Compared with traditional open surgery, laparoscopic surgery has the advantages of convenient operation and magnified field of view. Laparoscopic surgery has been successful in many fields, including gastrointestinal medicine and gynecology. The gallbladder was one of the first organs to be treated by laparoscopic surgery, and laparoscopic cholecystectomy has become the gold standard surgical treatment for benign gallbladder diseases. However, the safety and feasibility of laparoscopic surgery for patients with GC remain controversial. Over the past several decades, research has focused on laparoscopic surgery for GC. The disadvantages of laparoscopic surgery include a high incidence of gallbladder perforation, possible port site metastasis, and potential tumor seeding. The advantages of laparoscopic surgery include less intraoperative blood loss, shorter postoperative hospital stay, and fewer complications. Nevertheless, studies have provided contrasting conclusions over time. In general, recent research has tended to support laparoscopic surgery. However, the application of laparoscopic surgery in GC is still in the exploratory stage. Here, we provide an overview of previous studies, with the aim of introducing the application of laparoscopy in GC.

**Key Words:** Gallbladder carcinoma; Laparoscopic surgery; Open surgery; Gallbladder perforation; Port site metastases; Prognosis

Wu X, Li BL, Zheng CJ. Application of laparoscopic surgery in gallbladder carcinoma. *World J Clin Cases* 2023; In press

**Core Tip:** Gallbladder carcinoma (GC) is a rare cancer of the digestive system. Surgery is the main treatment strategy for this disease. The gallbladder was one of the first organs to undergo laparoscopic surgery. However, the safety and feasibility of laparoscopic surgery in patients with GC remain controversial. The disadvantages and advantages of laparoscopic surgery have been reported by different studies. In general, recent studies have tended to support laparoscopic surgery by experienced surgeons in selected patients. Clinical research with high-level evidence is required to validate the existing conclusions.

**INTRODUCTION**

Since the second half of the last century, noncommunicable diseases have replaced infectious diseases as the main global health concern[1]. Specifically, over 75% of premature deaths among individuals aged 30–70 years are caused by noncommunicable diseases[1]; cardiovascular disease and cancer are the main culprits. Based on current trends, cancer is expected to surpass cardiovascular diseases and become the leading cause of premature death during this century[2]. More than 80% of all countries have formulated cancer control plans; however, detailed evidence-based programs that are tailored to resource levels remain lacking[3]. Digestive system tumors, such as gastric and colon cancer, account for a high proportion of the global cancer incidence and mortality rates[4,5]. Gallbladder carcinoma (GC) is a relatively rare gastrointestinal tumor. According to the 2018 global cancer estimates of incidence and mortality, its morbidity and mortality rates account for 1.2% and 1.7% of all tumors, ranking 22nd[5]. In the 2020 edition, the incidence and mortality rates account for 0.6% and 0.9% of all tumors, ranking 25th[4]. Furthermore, the incidence of GC varies greatly by country and region[6]. For example, in China, where the incidence is high, an estimated 30–50 thousand new cases and 25–40 thousand deaths occur annually[7,8], while in the United States, where the incidence is low, an estimated 4–10 thousand new cases and 2–4 thousand deaths occur each year[8,9]. The therapeutic outcome of GC remains unsatisfactory, with a median survival time of approximately 25 mo after curative resection[10,11]. Surgery is the only potential cure for GC[6,11], and selecting a reasonable surgical extent and approach for individual patients is crucial. Moreover, laparoscopic technology has developed rapidly since its application in the field of surgery[12-15], and favorable outcomes of laparoscopic surgery for GC have been achieved[16-18]. However, the safety and feasibility of laparoscopic surgery for patients with GC remain controversial[19]. The present paper aims to review the changes in tumor staging of GC, the application of laparoscopic techniques in surgery, and the advantages and disadvantages of laparoscopic surgery for GC, in order to analyze the safety and effectiveness of laparoscopic surgery for patients with GC.

**TUMOR STAGING OF GC**

Tumor staging is vital to determine the subsequent treatment and prognosis. The American Joint Committee on Cancer (AJCC) cancer staging system is the most commonly used and widely accepted tumor staging system. The AJCC staging system stages GC according to the depth of tumor invasion, lymph node status, and distant metastases[20]. Specifically, T staging is based mainly on the depth of invasion of the gallbladder wall, as well as the direct invasion of the liver and other surrounding organs (Table 1). N staging is based primarily on the number of positive lymph nodes (Table 2), and M staging is based on the presence or absence of distant metastases. However, GC staging differs significantly between the 7th and 8th editions of the AJCC staging system. The changes are based on the biological behavior and prognosis of different tumor stages. Identifying the stage of the tumor and the content of the stage change is crucial for the selection of appropriate treatment, especially when deciding whether the tumor is suitable for laparoscopic surgery.

Two main changes were made from the AJCC 7th edition to the AJCC 8th edition of GC tumor staging. First, the T2 stage has been further classified according to the tumor location as T2a (peritoneal side) and T2b (hepatic side). T2b exhibits a worse prognosis than T2a[21]. Second, N staging is no longer based on the location of lymph node metastases, but rather on the number of lymph node metastases, which is correlated with the prognosis[22]. These changes have practical implications for laparoscopic surgery in patients with GC. For example, no-touch radical excision is more feasible for T2a tumors than T2b tumors. Moreover, at least six lymph nodes must be resected and evaluated[23,24], including in laparoscopic surgery.

**APPLICATION OF LAPAROSCOPIC TECHNIQUE IN SURGERY**

The advent of laparoscopy has revolutionized surgery. Compared with traditional open surgery, laparoscopic surgery has the advantages of convenient operation and magnified field of view. It allows surgeons to see the details of the interior of the abdominal cavity, providing better operating conditions. Surgeons can perform a variety of complex operations by manipulating various movements of the sticks, avoiding blood stains on the gloves and direct contact of hands and organs. Additionally, for patients, the long scar on the abdomen from open surgery is replaced by a few small holes, which facilitates physical and psychological recovery. Laparoscopic techniques have been successful in most aspects of surgery. For example, for laparoscopic gastrectomy, numerous clinical studies have reported no differences from open surgery in postoperative complications, mortality, and oncological outcomes[25-28]. Laparoscopic gastrectomy leads to less blood loss, shorter hospital stays, and faster return of bowel function, at the expense of longer operation times. Due to the short- and long-term advantages, laparoscopic gastrectomy has been recommended in many national guidelines[29]. Moreover, laparoscopic liver resection has demonstrated better surgical outcomes, such as duration of hospitalization and postoperative complication rates, with similar overall survival and disease-free survival times, compared with open liver resection[30]. Due to the widespread application of laparoscopic liver resection, the International Laparoscopic Liver Society was formed in 2016 by a group of experts[31]. Single-incision and robot-assisted technology are also available for minimally invasive liver surgery[32,33]. Additionally, laparoscopic techniques have achieved great success in the treatment of adrenal, prostate, and rectal diseases, among others[34-36]. For some established laparoscopic procedures, such as cholecystectomy, different methods and port numbers have been reported[37]. Laparoscopic surgery has also been combined with endoscopic techniques to treat concomitant gallstones and common bile duct stones, early gastric cancer, gastrointestinal stromal tumors, and other diseases[38-40]. Compared with its relatively established application in gastrointestinal surgery, the application of laparoscopic surgery in GC is still in the exploratory stage.

**LAPAROSCOPIC SURGERY FOR GC**

The gallbladder was one of the first organs to undergo laparoscopic surgery. Mühe performed the first laparoscopic cholecystectomy (LC) in 1985, and Dubois began to regularly perform LC by 1988[41]. Thereon, the application of laparoscopic techniques in benign diseases of the gallbladder developed quickly, and LC has become the gold standard treatment for gallstones, gallbladder polyps, and other benign diseases. However, the application of laparoscopy in GC is far inferior to that in gastrointestinal tumors. The limitations include the clarity of the endoscopic field of view, the convenience of operation, and most importantly, the principles of no-touch surgery. Nevertheless, research over the past several decades has focused on laparoscopic surgery for GC.

***Research before 2000***

Since the application of LC, the safety of this operation has gained attention. The two major risks of laparoscopy for GC include gallbladder perforation and port site metastasis. As the gallbladder serves as a temporary storage site for bile, intraoperative perforation must be avoided. Sarli *et al*[42] performed a matched cohort analysis involving 1127 patients who underwent LC. Intraoperative gallbladder perforation occurred in more than 10% of patients (131/1127), and the only risk factor associated with gallbladder perforation was the surgeon's experience. Moreover, a study in Italy of 350 consecutive patients who underwent LC at the authors' hospital revealed that chronic cholecystitis, gallbladder hydrops, and a history of previous laparotomies were risk factors for gallbladder perforation during surgery[43]. Specifically, the probability of intraoperative gallbladder perforation was 3.5% among patients with no risk factors and up to 25% among those with all risk factors. Accidental bile spillage induced by gallbladder perforation during surgery may result in tumor implantation and metastasis, which is one of the greatest concerns of laparoscopic surgery for GC. With the widespread application of laparoscopic technology in gastroenterology and gynecology, whether laparoscopic surgery could result in tumor seeding in patients with GC and other abdominal tumors has been studied. A questionnaire study from Germany, Switzerland, and Austria including 117840 patients that underwent LC (including 409 cases of incidental GC) and 412 patients that underwent laparoscopic colorectal procedures found that 109 patients experienced tumor recurrence[44]. Thus, laparoscopic surgery for cancer exhibited a higher rate of abdominal wall metastasis than that of open surgery, and the use of plastic retrieval bags and an intact tumor specimen did not eliminate the possibility of port site recurrence. Furthermore, Z'graggen *et al*[45] studied 37 patients with preoperatively unknown gallbladder adenocarcinoma and found that these patients had a high rate of port site recurrence, which increased in cases of gallbladder perforation. Additionally, a national, multicenter study from Sweden involving data from 30 hospitals, including 11976 LCs, found that, of 447 patients with GC, 270 had their gallbladder removed, 55 underwent laparoscopic surgery, and 9 exhibited port site metastasis[46]. The researchers inferred that port site metastases are common and recommended open surgery in cases of suspected GC. In addition to gallbladder perforation and port site metastasis, pneumoperitoneum is also expected to be associated with poor prognosis[44]. For these reasons, many researchers have proposed that laparoscopic surgery is more appropriate for patients with early-stage GC. In addition, Wibbenmeyer *et al*[47] identified 9 patients with GC out of 928 patients who underwent cholecystectomy and reported that this procedure was suitable for patients with GC confined to the mucosa. Overall, early studies on laparoscopic surgery for GC focused primarily on the risks of laparoscopic technology.

***Research from 2000 to 2010***

After a period of application, the focus of research on laparoscopic surgery for GC shifted from the risks of surgery to the changes in the treatment of GC. However, intraoperative gallbladder perforation remained an issue. A Japanese survey of 498 patients with GC revealed that approximately 20% of patients who underwent LC experienced gallbladder perforation during surgery, and their survival rate was significantly lower than that of patients without gallbladder perforation[48]. Recommendations have also been made for unsuspected GC after LC. Steinert *et al*[49] reviewed the studies regarding GC and LC and recommended a radical procedure and additional port site excision after a postoperative diagnosis of stage ≥ T2 GC. A study from Japan identified 9 patients with unsuspected GC from a cohort of 1663 patients who underwent LC[50]. Five of the nine patients experienced tumor recurrence and died 4–37 mo after the initial operation. As a result, the authors emphasized the importance of preventing bile spillage. The widespread popularization of LC has also promoted the diagnosis and treatment of early-stage GC. Kokudo *et al*[51] retrospectively studied 152 patients with GC and found that the preoperative diagnostic accuracy for T and N staging was 52.6% and 24.5%, respectively. These low rates of preoperative diagnosis hinder the selection of appropriate treatment options. Shih *et al*[52] compared 53 patients with incidentally diagnosed GC and 54 patients with preoperatively diagnosed lesions. They found that LC could result in the early discovery of GC, likely improving patient prognosis. Moreover, Darabos and Stare[53] reviewed 3158 patients who underwent LC and 3083 who underwent classic cholecystectomies. They reported that more early-stage GC could be diagnosed and treated due to the increased use of LC, highlighting the importance of LC for early-stage GC. Thus, advances in laparoscopic equipment and surgical techniques have played a distinct role in promoting the development of laparoscopic surgery for GC.

***Research from 2010 to 2020***

Research from 2010–2020 evaluated the relationship between bile spillage caused by intraoperative perforation and the prognosis of GC. In a Korean study, 12 patients with GC with intraoperative bile spillage were compared with 16 patients without bile spillage[54]. Both disease-free survival (71.4 *vs* 20.9 mo) and overall survival (72.6 *vs* 25.8 mo) were significantly shorter in the bile spillage group. The authors demonstrated that bile spillage was associated with incomplete resection and systemic recurrence, and they recommended that open surgery should be considered when GC is suspected. With the widespread use of retrieval bags, studies evaluated whether the routine use of retrieval bags would reduce the occurrence of port-site complications. A meta-analysis was performed to investigate the role of retrieval bags in LC, but no significant benefit in reducing the infection rate was found[55]. Despite concerns of the risks of laparoscopic surgery, a growing number of studies began to suggest its advantages[56-59]. For example, Goetze and Paolucci[60] used the German Registry system and analyzed 837 patients with incidental GC. They divided the patients into three groups: A laparoscopic approach group, an open surgery group, and an initially laparoscopic approach but converted to open surgery group. The laparoscopic approach was associated with significantly better 5-year survival rates and had similar accidental intraoperative perforation rates and recurrence rates to those of open surgery. Moreover, Yoon *et al*[61] performed a 10-year prospective cohort study, including 45 patients with GC (Tis, *n* = 2; T1a, *n* = 10; T1b, *n* = 8; T2, *n* = 25). The disease-specific survival rate was 92.3%, and the authors considered the long-term prognosis to be favorable and recommended laparoscopic surgery for selected patients. Furthermore, Jang *et al*[62] studied 197 patients with stage T1 GC and reported that the 5-year disease-specific survival rates were similar in patients who underwent LC and open cholecystectomy, as well as in patients underwent extended and simple cholecystectomy. Due to the advantages of a shorter hospital stay, less blood loss, and better cosmetic outcomes, they recommended LC to be performed by highly experienced surgeons as standard treatment for stage T1 GC. Moreover, Itano *et al*[63] studied 19 patients with suspected stage T2 GC and reported that the laparoscopic surgery group had lower intraoperative blood loss (104 *vs* 584 mL), shorter postoperative hospital stays (9.1 *vs* 21.6 d), and similar operative times (309 *vs* 324 min) and numbers of harvested lymph nodes (12.6 *vs* 10.2) compared with the open surgery group. They also reported no cases of recurrence after a mean follow-up time of 37 mo. Hence, the authors recommended laparoscopic surgery as the preferred strategy for suspected stage T2 GC. In a retrospective study from India, 24 patients who underwent radical LC were compared with 46 patients who underwent radical open cholecystectomy[64]. Compared with the open group, the laparoscopic group had longer operating times (270 *vs* 240 min), lower blood loss (200 *vs* 275 mL), and similar mortality and lymph node yield. Thus, these authors also recommended radical LC for selected patients with GC. Shirobe and Maruyama[65] reported a study on 11 patients with GC who underwent radical LC with lymph node dissection. The 5-year survival rates of patients with stages T1b and T2 GC were 100% and 83.3%, respectively. Therefore, the authors recommended exclusive laparoscopic surgery for patients with stages T1b and T2 GC. Due to the advances in laparoscopic technology, even reoperation for incidental GC can be completed laparoscopically[66,67]. Moreover, laparoscopic resection of the hepatoduodenal ligament and IVb-V segments could be performed appropriately and safely at experienced centers. Although controversy remains, laparoscopic surgery has become more common for GC due to its rapid development and proven efficacy for other types of abdominal tumors.

***Research from 2020 and beyond***

In recent years, more studies have been conducted on laparoscopic surgery for GC. Because of the development of high-definition display equipment, the refinement of surgical equipment, and the technical progress of surgeons, current research supports the application of laparoscopic surgery for GC. Kim *et al*[68] performed a propensity analysis to compare the outcomes of pure extended LC and open extended cholecystectomy. They found that extended LC resulted in shorter postoperative hospital stays (7 *vs* 12 d) and similar complication rates and disease-free survival rates compared with open surgery. Moreover, Navarro *et al*[69] performed a propensity score-matched analysis of patients with stage T2 GC. They compared 43 patients who underwent radical LC with 43 who underwent open radical cholecystectomy and found that the LC group had a shorter hospital stay, lesser blood loss, fewer complications, and similar 5-year overall and disease-free survival rates compared with open surgery group. Similarly, Wang *et al*[18] retrospectively reviewed 106 patients with incidental GC after LC. All patients underwent reoperation, and radical laparoscopic reoperation resulted in better 1-year (95.56% *vs* 86.89%) and 5-year (44.44% *vs* 29.51%) survival rates, lesser blood loss (100 ± 25.4 *vs* 200 ± 45.6 mL), shorter hospital stays (3.5 ± 1.9 *vs* 5.6 ± 2.7 d), and lower complication rates (6.7% *vs* 13.1%) compared with open surgery. In addition, a study from China included 50 patients with GC and found that laparoscopic surgery was associated with a shorter postoperative hospital stay (6.2 ± 2.4 *vs* 8.6 ± 2.3 d) and lesser intraoperative blood loss (242 ± 108.5 *vs* 401 ± 130.3 mL)[70]. Moreover, Bakos *et al*[71] reported a study of 47 patients with GC and found that LC could diagnose GC at an early stage in some patients[71]. Cho *et al*[72] performed a propensity score-matched analysis to evaluate the effects of laparoscopic surgery on patients with stage T2 GC. Compared with the open surgery group, the laparoscopic surgery group showed significant advantages in terms of operation time (316.8 ± 80.3 *vs* 218.9 ± 145.0 min) and postoperative hospital stay (14.4 ± 6.0 *vs* 8.4 ± 5.9 d). However, the 3-year overall and disease-free survival rates were similar between the laparoscopic and open surgery groups. Hamad *et al*[73] used the National Cancer Database to investigate the impact of different operative approaches on lymph node evaluation and yield. They identified 2014 patients and found that patients who underwent open and minimally invasive surgery had similar lymph node evaluation and yield rates. Due to the difficulty in diagnosing GC by only imaging tests before surgery, Tokumitsu *et al*[74] reported and recommended their novel approach using whole-layer LC and gallbladder bed dissection, which could serve as an optimal treatment strategy. Imamura *et al*[75] evaluated 13 patients who underwent whole-layer LC and 18 who underwent laparoscopic gallbladder bed resection, and reported that their surgical strategy was curative and safe.

Systematic reviews have also provided evidence supporting the use of laparoscopic surgery for GC. Liu *et al*[76] systematically reviewed 24 studies of minimally invasive surgery for GC and found that minimally invasive surgery for GC could be performed safely in selected patients by experienced surgeons. Feng *et al*[77] performed a systematic review and meta-analysis of 15 studies with a total of 1068 patients and found no significant differences in the 1-, 3-, and 5-year overall survival rates, intraoperative blood loss, operation time, number of harvested lymph nodes, or complication rates between laparoscopic and open surgery. However, the length of hospitalization was shorter in the laparoscopic group. This review revealed that laparoscopic surgery is as safe and feasible as open surgery in patients with early-stage GC.

With the advancement of laparoscopic technology, some complex operations can now be performed laparoscopically. For example, a patient with synchronous GC and extrahepatic cholangiocarcinoma underwent successful laparoscopic hepatopancreaticoduodenectomy[78]. Additionally, a patient with postoperatively diagnosed GC underwent successful laparoscopic bile duct resection with lymph node dissection and was discharged on postoperative day 4[17]. Nevertheless, although great care is taken to protect the port site, port site metastasis still occurs on occasion[79,80]. Moreover, the use of retrieval bags has been recommended as the gold standard[80]. While recent studies focus on the advantages of laparoscopic surgery for GC, it remains controversial. Finally, most existing studies have focused on early and mid-stage GC, recommending that laparoscopic surgery be performed by experienced surgeons.

**CURRENT SITUATION AND DEVELOPING TREND**

Although laparoscopic technique has been widely used in patients with GC and many studies have obtained positive results, it is not recommended by current guidelines. The Japanese Society of Hepato-Biliary-Pancreatic Surgery (JSHBPS) published their clinical practice guidelines for the management of biliary tract cancers in 2007, and updated them twice in 2015 and 2020[19,81]. As the only guidelines that provide the management of all biliary tract malignant diseases, the JSHBPS recommends open cholecystectomy as a rule for patients with suspected GC. They suggested that laparoscopic surgery could be performed as a clinical study with informed consent. Meanwhile, in the guideline for the diagnosis and treatment of GC (2019 edition), Branch of Biliary Surgery, Chinese Surgical Society and Chinese Committee of Biliary Surgeons do not recommend laparoscopic surgery for patients with GC[82]. Accumulation of evidence is awaited for the application of laparoscopic surgery in GC. In Table 3, we summarize the data of several existing studies in recent years. More studies are expected in the next few years.

The application of laparoscopic surgery in GC is in line with the concept of minimally invasive and Enhanced Recovery After Surgery (ERAS). Robotic surgery can be seen as an upgrade and advancement of laparoscopic surgery. It has also been used in patients with GC. Sucandy *et al*[83] reported a study of 15 consecutive patients with GC who underwent robotic surgery. No intraoperative complications were observed, and the median hospital stay was 3 d. Byun *et al*[84] reported 16 patients who underwent robotic extended cholecystectomy for suspected stage T2 or above GC. The mean operation time was 198 min, and the median hospital stay was 7 d. Robotic surgery has many advantages over open and laparoscopic surgery, especially regarding ergonomics[85]. Its role in the treatment of GC should be complementary to laparoscopic techniques. ERAS is a multidisciplinary and comprehensive patient management model[86-90]. This model aims to reduce the perioperative stress response, decrease complications, and shorten the length of hospitalization and has been proven effective for many types of surgery[91-93]. However, ERAS study on patients with GC is rare[94]. Laparoscopic surgery for GC can reduce trauma, accelerate patient recovery, and shorten hospital stay, which satisfies the requirements of ERAS. The development trend of laparoscopic surgery in GC is bound to include robotic surgery and ERAS management.

**CONCLUSION**

Laparoscopic surgery for GC is feasible, and a considerable amount of research has been conducted on the safety of this surgical strategy. While gallbladder perforation and port site metastasis are major concerns of laparoscopic surgery, many clinical studies have confirmed the advantages of laparoscopic surgery over open surgery in terms of operation time, intraoperative bleeding, and hospital stay, as well as their similarity regarding therapeutic efficacy. However, compared with its applications for gastrointestinal tumors, the application of laparoscopic surgery for GC is underdeveloped. Prospective, multicenter, randomized, and controlled clinical trials are required to further confirm the safety and feasibility of laparoscopic surgery for GC. Currently, laparoscopic surgery for GC should be conducted within reason, according to the tumor stage and experience of the surgeons.

**REFERENCES**

1 **Bray F**, Laversanne M, Weiderpass E, Soerjomataram I. The ever-increasing importance of cancer as a leading cause of premature death worldwide. *Cancer* 2021; **127**: 3029-3030 [PMID: 34086348 DOI: 10.1002/cncr.33587]

2 **NCD Countdown 2030 collaborators**. NCD Countdown 2030: pathways to achieving Sustainable Development Goal target 3.4. *Lancet* 2020; **396**: 918-934 [PMID: 32891217 DOI: 10.1016/S0140-6736(20)31761-X]

3 **Romero Y**, Trapani D, Johnson S, Tittenbrun Z, Given L, Hohman K, Stevens L, Torode JS, Boniol M, Ilbawi AM. National cancer control plans: a global analysis. *Lancet Oncol* 2018; **19**: e546-e555 [PMID: 30268693 DOI: 10.1016/S1470-2045(18)30681-8]

4 **Sung H**, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. *CA Cancer J Clin* 2021; **71**: 209-249 [PMID: 33538338 DOI: 10.3322/caac.21660]

5 **Bray F**, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. *CA Cancer J Clin* 2018; **68**: 394-424 [PMID: 30207593 DOI: 10.3322/caac.21492]

6 **Ganeshan D**, Kambadakone A, Nikolaidis P, Subbiah V, Subbiah IM, Devine C. Current update on gallbladder carcinoma. *Abdom Radiol (NY)* 2021; **46**: 2474-2489 [PMID: 33386907 DOI: 10.1007/s00261-020-02871-2]

7 **Chen W**, Zheng R, Baade PD, Zhang S, Zeng H, Bray F, Jemal A, Yu XQ, He J. Cancer statistics in China, 2015. *CA Cancer J Clin* 2016; **66**: 115-132 [PMID: 26808342 DOI: 10.3322/caac.21338]

8 **Xia C**, Dong X, Li H, Cao M, Sun D, He S, Yang F, Yan X, Zhang S, Li N, Chen W. Cancer statistics in China and United States, 2022: profiles, trends, and determinants. *Chin Med J (Engl)* 2022; **135**: 584-590 [PMID: 35143424 DOI: 10.1097/CM9.0000000000002108]

9 **Siegel RL**, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2022. *CA Cancer J Clin* 2022; **72**: 7-33 [PMID: 35020204 DOI: 10.3322/caac.21708]

10 **Buettner S**, Margonis GA, Kim Y, Gani F, Ethun CG, Poultsides GA, Tran T, Idrees K, Isom CA, Fields RC, Krasnick B, Weber SM, Salem A, Martin RC, Scoggins CR, Shen P, Mogal HD, Schmidt C, Beal E, Hatzaras I, Shenoy R, Maithel SK, Pawlik TM. Changing Odds of Survival Over Time among Patients Undergoing Surgical Resection of Gallbladder Carcinoma. *Ann Surg Oncol* 2016; **23**: 4401-4409 [PMID: 27495279 DOI: 10.1245/s10434-016-5470-2]

11 **Hickman L**, Contreras C. Gallbladder Cancer: Diagnosis, Surgical Management, and Adjuvant Therapies. *Surg Clin North Am* 2019; **99**: 337-355 [PMID: 30846038 DOI: 10.1016/j.suc.2018.12.008]

12 **Qin T**, Wang M, Zhang H, Li J, Deng X, Zhang Y, Zhao W, Fan Y, Li D, Chen X, Feng Y, Zhu S, Xing Z, Yu G, Xu J, Xie J, Dou C, Ma H, Liu G, Shao Y, Chen W, Xu S, Liu J, Liu J, Yin X, Qin R; Minimally Invasive Pancreas Treatment Group in the Pancreatic Disease Branch of China’s International Exchange and Promotion Association for Medicine and Healthcare. The Long-Term Outcome of Laparoscopic Resection for Perihilar Cholangiocarcinoma Compared with the Open Approach: A Real-World Multicentric Analysis. *Ann Surg Oncol* 2023; **30**: 1366-1378 [PMID: 36273058 DOI: 10.1245/s10434-022-12647-1]

13 **Li B**, Chen WB, Xia SL. A Comparison of Laparoscopic-Modified Kasai Versus Conventional Open Kasai for Biliary Atresia in Infants: A Single-Center Experience. *J Laparoendosc Adv Surg Tech A* 2023; **33**: 226-230 [PMID: 36270014 DOI: 10.1089/lap.2022.0339]

14 **Huang Z**, Li T, Zhang G, Zhou Z, Shi H, Tang C, Yang L, Lei X. Comparison of open, laparoscopic, and robotic left colectomy for radical treatment of colon cancer: a retrospective analysis in a consecutive series of 211 patients. *World J Surg Oncol* 2022; **20**: 345 [PMID: 36253768 DOI: 10.1186/s12957-022-02796-8]

15 **Zimmitti G**, Sijberden JP, Osei-Bordom D, Russolillo N, Aghayan D, Lanari J, Cipriani F, López-Ben S, Rotellar F, Fuks D, D'Hondt M, Primrose JN, Görgec B, Cacciaguerra AB, Marudanayagam R, Langella S, Vivarelli M, Ruzzenente A, Besselink MG, Alseidi A, Efanov M, Giuliante F, Dagher I, Jovine E, di Benedetto F, Aldrighetti LA, Cillo U, Edwin B, Ferrero A, Sutcliffe RP, Hilal MA. Indications, trends, and perioperative outcomes of minimally invasive and open liver surgery in non-obese and obese patients: An international multicentre propensity score matched retrospective cohort study of 9963 patients. *Int J Surg* 2022; **107**: 106957 [PMID: 36252942 DOI: 10.1016/j.ijsu.2022.106957]

16 **Ome Y**, Hashida K, Yokota M, Nagahisa Y, Okabe M, Kawamoto K. Laparoscopic approach to suspected T1 and T2 gallbladder carcinoma. *World J Gastroenterol* 2017; **23**: 2556-2565 [PMID: 28465640 DOI: 10.3748/wjg.v23.i14.2556]

17 **Han S**, Yoon YS, Han HS, Lee JS. Laparoscopic bile duct resection with lymph node dissection for gallbladder cancer diagnosed after laparoscopic cholecystectomy. *Surg Oncol* 2020; **35**: 475 [PMID: 33096445 DOI: 10.1016/j.suronc.2020.10.006]

18 **Wang Z**, Xu Y, Hu D, Wu X, Chen Y, Ye Q, Wang J, Zhu J. Laparoscopy Versus Open Reoperation for Incidental Gallbladder Carcinoma After Laparoscopic Cholecystectomy. *J Laparoendosc Adv Surg Tech A* 2020; **30**: 764-768 [PMID: 32429744 DOI: 10.1089/lap.2019.0802]

19 **Nagino M**, Hirano S, Yoshitomi H, Aoki T, Uesaka K, Unno M, Ebata T, Konishi M, Sano K, Shimada K, Shimizu H, Higuchi R, Wakai T, Isayama H, Okusaka T, Tsuyuguchi T, Hirooka Y, Furuse J, Maguchi H, Suzuki K, Yamazaki H, Kijima H, Yanagisawa A, Yoshida M, Yokoyama Y, Mizuno T, Endo I. Clinical practice guidelines for the management of biliary tract cancers 2019: The 3rd English edition. *J Hepatobiliary Pancreat Sci* 2021; **28**: 26-54 [PMID: 33259690 DOI: 10.1002/jhbp.870]

20 **Zhu AX,** Pawlik TM, Kooby DA, Schefter TE, Vauthey JN. Gallbladder. In: Amin MB, et al (eds.) AJCC Cancer Staging Manual. 8th edition. Chicago: Springer, 2017: 303-309

21 **Shindoh J**, de Aretxabala X, Aloia TA, Roa JC, Roa I, Zimmitti G, Javle M, Conrad C, Maru DM, Aoki T, Vigano L, Ribero D, Kokudo N, Capussotti L, Vauthey JN. Tumor location is a strong predictor of tumor progression and survival in T2 gallbladder cancer: an international multicenter study. *Ann Surg* 2015; **261**: 733-739 [PMID: 24854451 DOI: 10.1097/SLA.0000000000000728]

22 **Amini N**, Spolverato G, Kim Y, Gupta R, Margonis GA, Ejaz A, Pawlik TM. Lymph node status after resection for gallbladder adenocarcinoma: prognostic implications of different nodal staging/scoring systems. *J Surg Oncol* 2015; **111**: 299-305 [PMID: 25312786 DOI: 10.1002/jso.23813]

23 **Liu GJ**, Li XH, Chen YX, Sun HD, Zhao GM, Hu SY. Radical lymph node dissection and assessment: Impact on gallbladder cancer prognosis. *World J Gastroenterol* 2013; **19**: 5150-5158 [PMID: 23964151 DOI: 10.3748/wjg.v19.i31.5150]

24 **Ito H**, Ito K, D'Angelica M, Gonen M, Klimstra D, Allen P, DeMatteo RP, Fong Y, Blumgart LH, Jarnagin WR. Accurate staging for gallbladder cancer: implications for surgical therapy and pathological assessment. *Ann Surg* 2011; **254**: 320-325 [PMID: 21617582 DOI: 10.1097/SLA.0b013e31822238d8]

25 **Kim W**, Kim HH, Han SU, Kim MC, Hyung WJ, Ryu SW, Cho GS, Kim CY, Yang HK, Park DJ, Song KY, Lee SI, Ryu SY, Lee JH, Lee HJ; Korean Laparo-endoscopic Gastrointestinal Surgery Study (KLASS) Group. Decreased Morbidity of Laparoscopic Distal Gastrectomy Compared With Open Distal Gastrectomy for Stage I Gastric Cancer: Short-term Outcomes From a Multicenter Randomized Controlled Trial (KLASS-01). *Ann Surg* 2016; **263**: 28-35 [PMID: 26352529 DOI: 10.1097/SLA.0000000000001346]

26 **Greenleaf EK**, Sun SX, Hollenbeak CS, Wong J. Minimally invasive surgery for gastric cancer: the American experience. *Gastric Cancer* 2017; **20**: 368-378 [PMID: 26961133 DOI: 10.1007/s10120-016-0605-5]

27 **Huang C**, Liu H, Hu Y, Sun Y, Su X, Cao H, Hu J, Wang K, Suo J, Tao K, He X, Wei H, Ying M, Hu W, Du X, Yu J, Zheng C, Liu F, Li Z, Zhao G, Zhang J, Chen P, Li G; Chinese Laparoscopic Gastrointestinal Surgery Study (CLASS) Group. Laparoscopic vs Open Distal Gastrectomy for Locally Advanced Gastric Cancer: Five-Year Outcomes From the CLASS-01 Randomized Clinical Trial. *JAMA Surg* 2022; **157**: 9-17 [PMID: 34668963 DOI: 10.1001/jamasurg.2021.5104]

28 **Hyung WJ**, Yang HK, Park YK, Lee HJ, An JY, Kim W, Kim HI, Kim HH, Ryu SW, Hur H, Kim MC, Kong SH, Cho GS, Kim JJ, Park DJ, Ryu KW, Kim YW, Kim JW, Lee JH, Han SU; Korean Laparoendoscopic Gastrointestinal Surgery Study Group. Long-Term Outcomes of Laparoscopic Distal Gastrectomy for Locally Advanced Gastric Cancer: The KLASS-02-RCT Randomized Clinical Trial. *J Clin Oncol* 2020; **38**: 3304-3313 [PMID: 32816629 DOI: 10.1200/JCO.20.01210]

29 **Ong CT**, Schwarz JL, Roggin KK. Surgical considerations and outcomes of minimally invasive approaches for gastric cancer resection. *Cancer* 2022; **128**: 3910-3918 [PMID: 36191278 DOI: 10.1002/cncr.34440]

30 **Wang Q**, Li HJ, Dai XM, Xiang ZQ, Zhu Z. Laparoscopic versus open liver resection for hepatocellular carcinoma in elderly patients: Systematic review and meta-analysis of propensity-score matched studies. *Int J Surg* 2022; **105**: 106821 [PMID: 35948187 DOI: 10.1016/j.ijsu.2022.106821]

31 **Cherqui D**, Wakabayashi G, Geller DA, Buell JF, Han HS, Soubrane O, O'Rourke N; International Laparoscopic Liver Society. The need for organization of laparoscopic liver resection. *J Hepatobiliary Pancreat Sci* 2016; **23**: 665-667 [PMID: 27770492 DOI: 10.1002/jhbp.401]

32 **Chuang SH**, Chuang SC. Single-incision laparoscopic surgery to treat hepatopancreatobiliary cancer: A technical review. *World J Gastroenterol* 2022; **28**: 3359-3369 [PMID: 36158268 DOI: 10.3748/wjg.v28.i27.3359]

33 **Shimizu A**, Ito M, Lefor AK. Laparoscopic and Robot-Assisted Hepatic Surgery: An Historical Review. *J Clin Med* 2022; **11** [PMID: 35743324 DOI: 10.3390/jcm11123254]

34 **Xia Z**, Liu H, Gu P, He Z, Li J, Yang F, Tu H, Wu J, Liu X. Peri- and postoperative outcomes of laparoscopic adrenalectomy in nonobese versus obese patients: a systematic review and meta-analysis. *Wideochir Inne Tech Maloinwazyjne* 2022; **17**: 430-440 [PMID: 36187061 DOI: 10.5114/wiitm.2022.116407]

35 **Moretti TBC**, Magna LA, Reis LO. Surgical Results and Complications for Open, Laparoscopic, and Robot-assisted Radical Prostatectomy: A Reverse Systematic Review. *Eur Urol Open Sci* 2022; **44**: 150-161 [PMID: 36110904 DOI: 10.1016/j.euros.2022.08.015]

36 **Kim G**, Lee KY. Single-incision versus conventional laparoscopic surgery for rectal cancer: a meta-analysis of clinical and pathological outcomes. *Wideochir Inne Tech Maloinwazyjne* 2022; **17**: 387-405 [PMID: 36187059 DOI: 10.5114/wiitm.2022.118158]

37 **Lin H**, Zhang J, Li X, Li Y, Su S. Comparative outcomes of single-incision laparoscopic, mini-laparoscopic, four-port laparoscopic, three-port laparoscopic, and single-incision robotic cholecystectomy: a systematic review and network meta-analysis. *Updates Surg* 2023; **75**: 41-51 [PMID: 36205830 DOI: 10.1007/s13304-022-01387-2]

38 **Zhu J**, Wang G, Xie B, Jiang Z, Xiao W, Li Y. Minimally invasive management of concomitant gallstones and common bile duct stones: an updated network meta-analysis of randomized controlled trials. *Surg Endosc* 2023; **37**: 1683-1693 [PMID: 36278995 DOI: 10.1007/s00464-022-09723-8]

39 **Zhao PY**, Ma ZF, Jiao YN, Yan Y, Li SY, Du XH. Laparoscopic and endoscopic cooperative surgery for early gastric cancer: Perspective for actual practice. *Front Oncol* 2022; **12**: 969628 [PMID: 36263224 DOI: 10.3389/fonc.2022.969628]

40 **Teng TZJ**, Ishraq F, Chay AFT, Tay KV. Lap-Endo cooperative surgery (LECS) in gastric GIST: updates and future advances. *Surg Endosc* 2023; **37**: 1672-1682 [PMID: 36220988 DOI: 10.1007/s00464-022-09691-z]

41 **Giger U**, Michel JM, Vonlanthen R, Becker K, Kocher T, Krähenbühl L. Laparoscopic cholecystectomy in acute cholecystitis: indication, technique, risk and outcome. *Langenbecks Arch Surg* 2005; **390**: 373-380 [PMID: 15316783 DOI: 10.1007/s00423-004-0509-4]

42 **Sarli L**, Pietra N, Costi R, Grattarola M. Gallbladder perforation during laparoscopic cholecystectomy. *World J Surg* 1999; **23**: 1186-1190 [PMID: 10501883 DOI: 10.1007/s002689900644]

43 **De Simone P**, Donadio R, Urbano D. The risk of gallbladder perforation at laparoscopic cholecystectomy. *Surg Endosc* 1999; **13**: 1099-1102 [PMID: 10556446 DOI: 10.1007/s004649901181]

44 **Paolucci V**, Schaeff B, Schneider M, Gutt C. Tumor seeding following laparoscopy: international survey. *World J Surg* 1999; **23**: 989-95; discussion 996-7 [PMID: 10512937 DOI: 10.1007/s002689900613]

45 **Z'graggen K**, Birrer S, Maurer CA, Wehrli H, Klaiber C, Baer HU. Incidence of port site recurrence after laparoscopic cholecystectomy for preoperatively unsuspected gallbladder carcinoma. *Surgery* 1998; **124**: 831-838 [PMID: 9823395]

46 **Lundberg O**, Kristoffersson A. Port site metastases from gallbladder cancer after laparoscopic cholecystectomy. Results of a Swedish survey and review of published reports. *Eur J Surg* 1999; **165**: 215-222 [PMID: 10231654 DOI: 10.1080/110241599750007072]

47 **Wibbenmeyer LA**, Wade TP, Chen RC, Meyer RC, Turgeon RP, Andrus CH. Laparoscopic cholecystectomy can disseminate in situ carcinoma of the gallbladder. *J Am Coll Surg* 1995; **181**: 504-510 [PMID: 7582223]

48 **Ouchi K**, Mikuni J, Kakugawa Y; Organizing Committee, The 30th Annual Congress of the Japanese Society of Biliary Surgery. Laparoscopic cholecystectomy for gallbladder carcinoma: results of a Japanese survey of 498 patients. *J Hepatobiliary Pancreat Surg* 2002; **9**: 256-260 [PMID: 12140616 DOI: 10.1007/s005340200028]

49 **Steinert R**, Nestler G, Sagynaliev E, Müller J, Lippert H, Reymond MA. Laparoscopic cholecystectomy and gallbladder cancer. *J Surg Oncol* 2006; **93**: 682-689 [PMID: 16724350 DOI: 10.1002/jso.20536]

50 **Yamamoto H**, Hayakawa N, Kitagawa Y, Katohno Y, Sasaya T, Takara D, Nagino M, Nimura Y. Unsuspected gallbladder carcinoma after laparoscopic cholecystectomy. *J Hepatobiliary Pancreat Surg* 2005; **12**: 391-398 [PMID: 16258808 DOI: 10.1007/s00534-005-0996-x]

51 **Kokudo N**, Makuuchi M, Natori T, Sakamoto Y, Yamamoto J, Seki M, Noie T, Sugawara Y, Imamura H, Asahara S, Ikari T. Strategies for surgical treatment of gallbladder carcinoma based on information available before resection. *Arch Surg* 2003; **138**: 741-50; discussion 750 [PMID: 12860755 DOI: 10.1001/archsurg.138.7.741]

52 **Shih SP**, Schulick RD, Cameron JL, Lillemoe KD, Pitt HA, Choti MA, Campbell KA, Yeo CJ, Talamini MA. Gallbladder cancer: the role of laparoscopy and radical resection. *Ann Surg* 2007; **245**: 893-901 [PMID: 17522515 DOI: 10.1097/SLA.0b013e31806beec2]

53 **Darabos N**, Stare R. Gallbladder cancer: laparoscopic and classic cholecystectomy. *Surg Endosc* 2004; **18**: 144-147 [PMID: 14625757 DOI: 10.1007/s00464-002-9269-9]

54 **Lee JM**, Kim BW, Kim WH, Wang HJ, Kim MW. Clinical implication of bile spillage in patients undergoing laparoscopic cholecystectomy for gallbladder cancer. *Am Surg* 2011; **77**: 697-701 [PMID: 21679636]

55 **La Regina D**, Mongelli F, Cafarotti S, Saporito A, Ceppi M, Di Giuseppe M, Ferrario di Tor Vajana A. Use of retrieval bag in the prevention of wound infection in elective laparoscopic cholecystectomy: is it evidence-based? A meta-analysis. *BMC Surg* 2018; **18**: 102 [PMID: 30453917 DOI: 10.1186/s12893-018-0442-z]

56 **Palanisamy S**, Patel N, Sabnis S, Palanisamy N, Vijay A, Palanivelu P, Parthasarthi R, Chinnusamy P. Laparoscopic radical cholecystectomy for suspected early gall bladder carcinoma: thinking beyond convention. *Surg Endosc* 2016; **30**: 2442-2448 [PMID: 26416372 DOI: 10.1007/s00464-015-4495-0]

57 **Kim S**, Yoon YS, Han HS, Cho JY, Choi Y. Laparoscopic extended cholecystectomy for T3 gallbladder cancer. *Surg Endosc* 2018; **32**: 2984-2985 [PMID: 29218663 DOI: 10.1007/s00464-017-5952-8]

58 **Nitta T**, Kataoka J, Ohta M, Takashima Y, Fujii K, Ishii M, Inoue Y, Takeshita A, Ishibashi T. Laparoscopic Excisional Cholecystectomy with Full-Thickness Frozen Biopsy in Suspected Gallbladder Carcinoma. *Case Rep Gastroenterol* 2018; **12**: 747-756 [PMID: 30686959 DOI: 10.1159/000495603]

59 **Feng JW**, Yang XH, Liu CW, Wu BQ, Sun DL, Chen XM, Jiang Y, Qu Z. Comparison of Laparoscopic and Open Approach in Treating Gallbladder Cancer. *J Surg Res* 2019; **234**: 269-276 [PMID: 30527484 DOI: 10.1016/j.jss.2018.09.025]

60 **Goetze TO**, Paolucci V. Prognosis of incidental gallbladder carcinoma is not influenced by the primary access technique: analysis of 837 incidental gallbladder carcinomas in the German Registry. *Surg Endosc* 2013; **27**: 2821-2828 [PMID: 23404149 DOI: 10.1007/s00464-013-2819-5]

61 **Yoon YS**, Han HS, Cho JY, Choi Y, Lee W, Jang JY, Choi H. Is Laparoscopy Contraindicated for Gallbladder Cancer? A 10-Year Prospective Cohort Study. *J Am Coll Surg* 2015; **221**: 847-853 [PMID: 26272017 DOI: 10.1016/j.jamcollsurg.2015.07.010]

62 **Jang JY**, Heo JS, Han Y, Chang J, Kim JR, Kim H, Kwon W, Kim SW, Choi SH, Choi DW, Lee K, Jang KT, Han SS, Park SJ. Impact of Type of Surgery on Survival Outcome in Patients With Early Gallbladder Cancer in the Era of Minimally Invasive Surgery: Oncologic Safety of Laparoscopic Surgery. *Medicine (Baltimore)* 2016; **95**: e3675 [PMID: 27258495 DOI: 10.1097/MD.0000000000003675]

63 **Itano O**, Oshima G, Minagawa T, Shinoda M, Kitago M, Abe Y, Hibi T, Yagi H, Ikoma N, Aiko S, Kawaida M, Masugi Y, Kameyama K, Sakamoto M, Kitagawa Y. Novel strategy for laparoscopic treatment of pT2 gallbladder carcinoma. *Surg Endosc* 2015; **29**: 3600-3607 [PMID: 25740638 DOI: 10.1007/s00464-015-4116-y]

64 **Agarwal AK**, Javed A, Kalayarasan R, Sakhuja P. Minimally invasive versus the conventional open surgical approach of a radical cholecystectomy for gallbladder cancer: a retrospective comparative study. *HPB (Oxford)* 2015; **17**: 536-541 [PMID: 25727091 DOI: 10.1111/hpb.12406]

65 **Shirobe T**, Maruyama S. Laparoscopic radical cholecystectomy with lymph node dissection for gallbladder carcinoma. *Surg Endosc* 2015; **29**: 2244-2250 [PMID: 25303926 DOI: 10.1007/s00464-014-3932-9]

66 **Muñoz C**, Marino C, Morales E. Totally laparoscopic radical cholecystectomy (lymphadenectomy and segment IVb-V liver resection) after incidental gallbladder carcinoma (with video). *J Visc Surg* 2018; **155**: 243-244 [PMID: 29307518 DOI: 10.1016/j.jviscsurg.2017.12.010]

67 **Machado MA**, Makdissi FF, Surjan RC. Totally Laparoscopic Hepatic Bisegmentectomy (s4b+s5) and Hilar Lymphadenectomy for Incidental Gallbladder Cancer. *Ann Surg Oncol* 2015; **22 Suppl 3**: S336-S339 [PMID: 26059653 DOI: 10.1245/s10434-015-4650-9]

68 **Kim WJ**, Lim TW, Park PJ, Choi SB, Kim WB. Safety and feasibility of pure laparoscopic extended cholecystectomy: comparison with the open technique in a propensity analysis at a single center. *Surg Endosc* 2021; **35**: 6166-6172 [PMID: 33409594 DOI: 10.1007/s00464-020-08112-3]

69 **Navarro JG**, Kang I, Hwang HK, Yoon DS, Lee WJ, Kang CM. Oncologic safety of laparoscopic radical cholecystectomy in pT2 gallbladder cancer: A propensity score matching analysis compared to open approach. *Medicine (Baltimore)* 2020; **99**: e20039 [PMID: 32443308 DOI: 10.1097/MD.0000000000020039]

70 **Regmi P**, Hu HJ, Chang-Hao Y, Liu F, Ma WJ, Ran CD, Wang JK, Paudyal A, Cheng NS, Li FY. Laparoscopic surgery for oncologic extended resection of T1b and T2 incidental gallbladder carcinoma at a high-volume center: a single-center experience in China. *Surg Endosc* 2021; **35**: 6505-6512 [PMID: 33174099 DOI: 10.1007/s00464-020-08146-7]

71 **Bakos M**, Jankovic T, Durdik S, Vrtik L. Gallbladder carcinoma - when to use laparoscopic approach? *Bratisl Lek Listy* 2021; **122**: 341-346 [PMID: 33848185 DOI: 10.4149/BLL\_2021\_058]

72 **Cho JK**, Kim JR, Jang JY, Kim HG, Kim JM, Kwag SJ, Park JH, Kim JY, Ju YT, Jeong CY. Comparison of the Oncological Outcomes of Open versus Laparoscopic Surgery for T2 Gallbladder Cancer: A Propensity-Score-Matched Analysis. *J Clin Med* 2022; **11** [PMID: 35566770 DOI: 10.3390/jcm11092644]

73 **Hamad A**, Cloyd JM, Dillhoff M, Manilchuk A, Pawlik TM, Tsung A, Ejaz A. Comparison of lymph node evaluation and yield among patients undergoing open and minimally invasive surgery for gallbladder adenocarcinoma. *Surg Endosc* 2021; **35**: 2223-2228 [PMID: 32430521 DOI: 10.1007/s00464-020-07635-z]

74 **Tokumitsu Y**, Shindo Y, Matsui H, Matsukuma S, Nakajima M, Yoshida S, Iida M, Suzuki N, Takeda S, Nagano H. Laparoscopic total biopsy for suspected gallbladder cancer: A case series. *Health Sci Rep* 2020; **3**: e156 [PMID: 32318627 DOI: 10.1002/hsr2.156]

75 **Imamura H**, Adachi T, Tanaka T, Matsushima H, Hara T, Soyama A, Hidaka M, Eguchi S. Feasibility and Safety of Laparoscopic Gallbladder Resection for Gallbladder Tumours. *Anticancer Res* 2022; **42**: 903-910 [PMID: 35093888 DOI: 10.21873/anticanres.15548]

76 **Liu F**, Wu ZR, Hu HJ, Jin YW, Ma WJ, Wang JK, Li FY. Current status and future perspectives of minimally invasive surgery in gallbladder carcinoma. *ANZ J Surg* 2021; **91**: 264-268 [PMID: 32627337 DOI: 10.1111/ans.16125]

77 **Feng X**, Cao JS, Chen MY, Zhang B, Juengpanich S, Hu JH, Topatana W, Li SJ, Shen JL, Xiao GY, Cai XJ, Yu H. Laparoscopic surgery for early gallbladder carcinoma: A systematic review and meta-analysis. *World J Clin Cases* 2020; **8**: 1074-1086 [PMID: 32258078 DOI: 10.12998/wjcc.v8.i6.1074]

78 **Yao GL**. Laparoscopic hepatopancreaticoduodenectomy for synchronous gallbladder cancer and extrahepatic cholangiocarcinoma: a case report. *World J Surg Oncol* 2022; **20**: 190 [PMID: 35681223 DOI: 10.1186/s12957-022-02628-9]

79 **Gao KJ**, Yan ZL, Yu Y, Guo LQ, Hang C, Yang JB, Zhang MC. Port-site metastasis of unsuspected gallbladder carcinoma with ossification after laparoscopic cholecystectomy: A case report. *World J Clin Cases* 2020; **8**: 5729-5736 [PMID: 33344567 DOI: 10.12998/wjcc.v8.i22.5729]

80 **Petryshyn N**, Dražić T, Hogendorf P, Strzelczyk J, Strzałka A, Szwedziak K, Durczyński A. Port site metastases a year after initial laparoscopic cholecystectomy. Should the use of retrieval bags during laparoscopic cholecystectomy be the new gold standard? *Pol Przegl Chir* 2021; **93**: 61-65 [PMID: 36169533 DOI: 10.5604/01.3001.0015.3280]

81 **Miyazaki M**, Yoshitomi H, Miyakawa S, Uesaka K, Unno M, Endo I, Ota T, Ohtsuka M, Kinoshita H, Shimada K, Shimizu H, Tabata M, Chijiiwa K, Nagino M, Hirano S, Wakai T, Wada K, Isayama H, Okusaka T, Tsuyuguchi T, Fujita N, Furuse J, Yamao K, Murakami K, Yamazaki H, Kijima H, Nakanuma Y, Yoshida M, Takayashiki T, Takada T. Clinical practice guidelines for the management of biliary tract cancers 2015: the 2nd English edition. *J Hepatobiliary Pancreat Sci* 2015; **22**: 249-273 [PMID: 25787274 DOI: 10.1002/jhbp.233]

82 **Branch of Biliary Surgery, Chinese Surgical Society**; Chinese Committee of Biliary Surgeons. [Guideline for the diagnosis and treatment of gallbladder carcinoma (2019 edition)]. *Zhonghua Wai Ke Za Zhi* 2020; **58**: 243-251 [PMID: 32241052 DOI: 10.3760/cma.j.cn112139-20200106-00014]

83 **Sucandy I**, Jabbar F, Syblis C, Crespo K, Ross S, Rosemurgy A. Robotic Central Hepatectomy for the Treatment of Gallbladder Carcinoma. Outcomes of Minimally Invasive Approach. *Am Surg* 2022; **88**: 348-351 [PMID: 34796733 DOI: 10.1177/00031348211047457]

84 **Byun Y**, Choi YJ, Kang JS, Han Y, Kim H, Kwon W, Jang JY. Robotic extended cholecystectomy in gallbladder cancer. *Surg Endosc* 2020; **34**: 3256-3261 [PMID: 32306112 DOI: 10.1007/s00464-020-07554-z]

85 **Wee IJY**, Kuo LJ, Ngu JC. A systematic review of the true benefit of robotic surgery: Ergonomics. *Int J Med Robot* 2020; **16**: e2113 [PMID: 32304167 DOI: 10.1002/rcs.2113]

86 **Joliat GR**, Kobayashi K, Hasegawa K, Thomson JE, Padbury R, Scott M, Brustia R, Scatton O, Tran Cao HS, Vauthey JN, Dincler S, Clavien PA, Wigmore SJ, Demartines N, Melloul E. Guidelines for Perioperative Care for Liver Surgery: Enhanced Recovery After Surgery (ERAS) Society Recommendations 2022. *World J Surg* 2023; **47**: 11-34 [PMID: 36310325 DOI: 10.1007/s00268-022-06732-5]

87 **Mata-Suarez SM**, Mc Loughlin S, Fraidenraij U, Alvarez AO. Enhanced recovery after surgery (ERAS) in Latin America: The story so far. *Best Pract Res Clin Obstet Gynaecol* 2022; **85**: 18-22 [PMID: 35995655 DOI: 10.1016/j.bpobgyn.2022.07.007]

88 **Roulin D**, Demartines N. Principles of enhanced recovery in gastrointestinal surgery. *Langenbecks Arch Surg* 2022; **407**: 2619-2627 [PMID: 35861873 DOI: 10.1007/s00423-022-02602-9]

89 **Petrucciani N**, Boru CE, Lauteri G, Silecchia G. A Narrative Review on Bariatric ERAS. *Chirurgia (Bucur)* 2022; **117**: 505-516 [PMID: 36318680 DOI: 10.21614/chirurgia.2754]

90 **Ding H**, Hai Y, Guan L, Liu Y, Pan A, Han B. The outcome of enhanced recovery after surgery vs. a traditional pathway in adolescent idiopathic scoliosis surgery: A retrospective comparative study. *Front Surg* 2022; **9**: 989119 [PMID: 36277279 DOI: 10.3389/fsurg.2022.989119]

91 **Tidadini F**, Trilling B, Quesada JL, Foote A, Sage PY, Bonne A, Arvieux C, Faucheron JL. Association between Enhanced Recovery After Surgery (ERAS) protocol, risk factors and 3-year survival after colorectal surgery for cancer in the elderly. *Aging Clin Exp Res* 2023; **35**: 167-175 [PMID: 36306111 DOI: 10.1007/s40520-022-02270-1]

92 **Angelico R**, Romano F, Riccetti C, Pellicciaro M, Toti L, Favi E, Cacciola R, Manzia TM, Tisone G. The Enhanced Recovery after Surgery (ERAS) Pathway Is a Safe Journey for Kidney Transplant Recipients during the "Extended Criteria Donor" Era. *Pathogens* 2022; **11** [PMID: 36297249 DOI: 10.3390/pathogens11101193]

93 **Düzgün Ö**, Özcan P, Özçelik MF. Did the ERAS Protocol Improve Our Results in Locally Advanced Gastric Cancer Surgery? *J Pers Med* 2022; **12** [PMID: 36294688 DOI: 10.3390/jpm12101549]

94 **Wu X**, Li BL, Sun J, Zheng CJ, He XD, Liu W, Hong T, Han XL. [Application of enhanced recovery after surgery in perioperative management of patients with gallbladder carcinoma]. *Zhonghua Wai Ke Za Zhi* 2022; **60**: 372-377 [PMID: 35272429 DOI: 10.3760/cma.j.cn112139-20220107-00013]

**Footnotes**

**Conflict-of-interest statement:** All theauthors report no relevant conflicts of interest for this article.

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/

**Provenance and peer review:** Invited article; Externally peer reviewed.

**Peer-review model:** Single blind

**Peer-review started:** December 10, 2022

**First decision:** February 7, 2023

**Article in press:**

**Specialty type:** Medicine, research and experimental

**Country/Territory of origin:** China

**Peer-review report’s scientific quality classification**

Grade A (Excellent): 0

Grade B (Very good): B

Grade C (Good): C

Grade D (Fair): D, D

Grade E (Poor): 0

**P-Reviewer:** Chowdhury D, United Kingdom; Hori T, Japan; Tenreiro N, Portugal **S-Editor:** Fan JR **L-Editor:** Wang TQ **P-Editor:**

**Table 1 Definition of T-stage for gallbladder carcinoma**

|  |  |
| --- | --- |
| **T category** | **T criteria** |
| Tx | Primary tumor cannot be assessed |
| T0 | No evidence of primary tumor |
| Tis | Carcinoma *in situ* |
| T1 | Tumor invades the lamina propria or muscular layer |
| T1a | Tumor invades the lamina propria |
| T1b | Tumor invades the muscular layer |
| T2 | Tumor invades the perimuscular connective tissue on the peritoneal side, without involvement of the serosa (visceral peritoneum) or tumor invades the perimuscular connective tissue on the hepatic side, with no extension into the liver |
| T2a | Tumor invades the perimuscular connective tissue on the peritoneal side, without involvement of the serosa (visceral peritoneum) |
| T2b | Tumor invades the perimuscular connective tissue on the hepatic side, with no extension into the liver |
| T3 | Tumor perforates the serosa (visceral peritoneum) and/or directly invades the liver and/or one other adjacent organ or structure, such as the stomach, duodenum, colon, pancreas, omentum, or extrahepatic bile ducts |
| T4 | Tumor invades the main portal vein or hepatic artery or invades two or more extrahepatic organs or structures |

According to the AJCC 2018 TNM classification, 8th edition.

**Table 2 Definition of N-stage for gallbladder carcinoma**

|  |  |
| --- | --- |
| **N category** | **N criteria** |
| Nx | Regional lymph nodes cannot be assessed |
| N0 | No regional lymph node metastasis |
| N1 | Metastases to one to three regional lymph nodes |
| N2 | Metastases to four or more regional lymph nodes |

According to the AJCC 2018 TNM classification, 8th edition.

**Table 3 Data of several existing studies in recent years**

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **No.** | **1** | **2** | **3** | **4** | **5** |
| Year | 2019 | 2021 | 2020 | 2021 | 2022 |
| Ref. | Feng *et al*[59] | Regmi *et al*[70] | Navarro *et al*[69] | Kim *et al*[68] | Cho *et al*[72] |
| Country | China | China | Korea | Korea | Korea |
| Number of patients (*n*) |  |  |  |  |  |
| Laparoscopy | 41 | 20 | 43 | 17 | 19 |
| Laparotomy | 61 | 30 | 43 | 17 | 19 |
| Operation time (min) |  |  |  |  |  |
| Laparoscopy | 137 ± 92 | 258.3 ± 72.5 | 139.1 ± 97.1 | 175 (160-180) | 218.9 ± 145.0 |
| Laparotomy | 168 ± 51 | 227.0 ± 59.8 | 211.2 ± 91.4 | 156 (120-191) | 316.8 ± 80.3 |
| *P* value | 0.058 | 0.101 | 0.001 | 0.370 | 0.016 |
| Blood loss (mL) |  |  |  |  |  |
| Laparoscopy | 358 ± 390 | 242 ± 108.5 | 71.6 ± 178.8 | 300 (300-500) | - |
| Laparotomy | 386 ± 391 | 401 ± 130.3 | 208.1 ± 242.2 | 300 (200-900) | - |
| *P* value | 0.732 | < 0.01 | 0.004 | 0.846 | - |
| Postoperative hospital stays (d) |  |  |  |  |  |
| Laparoscopy | 5 ± 3 | 6.2 ± 2.4 | 6.1 ± 9.8 | 7.0 (7.0-9.0) | 8.4 ± 5.91 |
| Laparotomy | 11 ± 5 | 8.6 ± 2.3 | 12.6 ± 5.5 | 12.0 (10.0-14.0) | 14.4 ± 6.01 |
| *P* value | < 0.001 | < 0.01 | 0.0001 | 0.009 | 0.004 |
| Perforation (*n*) |  |  |  |  |  |
| Laparoscopy | 8 | - | - | - | 0 |
| Laparotomy | 3 | - | - | - | 0 |
| *P* value | 0.069 | - | - | - | - |
| Recurrence and metastasis (*n*) |  |  |  |  |  |
| Laparoscopy | 12 | 2 | - | 3 | - |
| Laparotomy | 10 | 4 | - | 2 | - |
| *P* value | 0.121 | 0.722 | - | 0.446 | - |
| 3-yr survival rates |  |  |  |  |  |
| Laparoscopy | - | - | - | 71.5%2 | 88.9% |
| Laparotomy | - | - | - | 82.4%2 | 86.3% |
| *P* value | - | - | - | 0.94 | 0.660 |
| 5-yr survival rates |  |  |  |  |  |
| Laparoscopy | 51.9% | - | 64.0% | - | - |
| Laparotomy | 55.7% | - | 80.4% | - | - |
| *P* value | 0.453 | - | 0.214 | - | - |

1Hospital stays.

2Disease-free survival.